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Summary
Publication of the first efficacious large-scale HIV vaccine
trial in 2009 prompted fresh hope that design of a protect-
ive vaccine against HIV may be achievable. In this review
we explore the difficult task of eliciting protective immune
responses to HIV and highlight the hurdles that vaccine
design must still overcome.
Key words: HIV; HIV vaccine; vaccine; antibodies;
humoral immunity
The quest for an HIV vaccine
In the almost 30 years since HIV was identified as the caus-
ative agent of AIDS, molecular characterisation of HIV
pathogenesis has led to development and licensing of
roughly 30 HIV inhibitors. When administered in certain
combinations these drugs enable patients to control viral
load for many years [1]. As a result, the prognosis fol-
lowing infection in most developed countries has improved
dramatically, and AIDS-related deaths have been steadily
declining worldwide [2].
In contrast to the success of anti-retroviral treatment, the
search for an efficacious HIV vaccine has been slow to
yield positive results. Despite enormous efforts over the
past three decades, most attempts to design an HIV vaccine
regimen have proved ineffective and were abandoned in the
early stages of development. Only a handful of regimens
were assessed in phase II/III studies, and neither antibody-
nor T-cell-based vaccine regimens proved effective [3–7].
In 2009 the RV144 HIV Vaccine Trial, tailored to induce
protective antibody responses, was the first to report par-
tial efficacy with a 31% lower infection rate in vaccinees
than in individuals receiving placebo [8]. Despite this mod-
est effect, the results of this trial fostered fresh hopes that
design of a protective vaccine against HIV may be achiev-
able, and has focused unprecedented levels of resources on
both defining the protection correlates of this regimen and
the search for alternative approaches [9].
HIV vaccine design is at the crossroads. The recent iden-
tification of new antibodies which block HIV with unpar-
alleled potency [10–12], target a wide variety of strains
[13] and prevent infection in animal models [14–19] raise
further hopes that engaging protective humoral responses
to build an efficacious vaccine against HIV is possible.
However, difficulties in devising vaccines and determining
their efficacy have simultaneously highlighted the fact that
the correlates of protection against HIV acquisition still
await definition [20–22]. Additionally, as new means of
pre-exposure prophylaxis are identified, the window of op-
portunity for conventional efficacy testing of HIV vaccines
may soon be closing.
While HIV vaccine design has never experienced a period
of such potential and (justified) optimism, development
and testing may yet increase in complexity. In this review
we highlight recent successes in antibody-based vaccine
design and hurdles old and new that need to be overcome.
We believe these factors will shape the future of antibody-
based vaccine design, and need to be balanced in order to
make HIV vaccines an attainable goal in reality.
HIV vaccines – how might one work?
That an HIV vaccine is a desirable goal has never been
disputed. However, whether or not this goal is attainable
has been differentially reflected over the years [9, 23–27].
Vaccines are indisputably the ideal means of protecting
a large proportion of the healthy population [28]. They
are cost-effective and are designed to involve low risks in
use. When efficacious they confer immunity on individu-
als, and, importantly, if the required threshold of immu-
nity in the population is reached, a given pathogen can be
eradicated [29, 30]. Smallpox virus is the best example of
this, as the virus was officially declared eradicated in 1979,
21 years after the World Health Organization initiated a fo-
cused vaccination-based eradication programme [31]. The
more easily a virus is transmitted, the higher the degree of
immunity in the population that needs to be reached. This
factor has led to difficulties in eradicating the measles vir-
us, where it is estimated that over 90–95% of the popula-
tion would need to be vaccinated in order to halt the spread
of this highly contagious virus [32]. However, in the case of
HIV, where an easy accessible preventive measure is des-
perately needed, even a partially efficacious vaccine is cur-
rently considered highly desirable. Due to the comparat-
ively restricted transmission routes of HIV, individuals at
high risk of infection, such as men having sex with men
(MSM), sex workers or discordant couples, can be more
easily identified and targeted by preventive measures or,
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once available, vaccines. In fact, even without targeting to
high risk populations vaccination of a moderate proportion
of the population is expected to achieve a substantial reduc-
tion in HIV transmission and save millions of lives [33].
All currently licensed antiviral vaccines protect by eliciting
inhibitory antibodies [34]. HIV vaccine development also
initially focused on attempts to elicit neutralising antibod-
ies [9]. In addition, due to their confirmed protective role
in natural infection, and the difficulties encountered in an-
tibody based HIV vaccine design, vaccine strategies which
evoke cellular immunity to HIV infection are also sought
[25, 27].
Eliciting antibodies capable of neutralising the virus before
it enters and infects target cells appears to be an ideal
strategy for vaccine design. The mechanism of action and
prevalence of these HIV neutralising antibodies has been
studied in great depth over recent decades [35, 36]. Such
antibodies act by binding specifically to the only accessible
viral proteins on HIV’s outer surface, the envelope proteins
gp120 and gp41, arranged as trimers of gp120-gp41 het-
erodimers to form the so-called viral spikes [37, 38].
Depending on the region of the viral spike targeted, neut-
ralising antibodies can interfere with engagement of cel-
lular receptors or block fusion of the viral and host mem-
branes [35]. Preventing this first step in the viral life cycle
may be particularly important in HIV, which is capable of
integration into the host genome and can persist in a latent
state [39].
Whilst this activity is likely to be crucial for antibodies to
mediate sterilising immunity [40], increased attention has
recently been focused on the capacity of envelope binding
antibodies to mediate additional antiviral activities. These
antibody effector functions include immune complex form-
ation, complement recruitment, Fc-receptor mediated pha-
gocytosis and antibody dependent cellular cytotoxicity
[41]. It has recently been suggested that the last two must
be crucial for effective antibody-mediated immunity [42].
While neutralising antibodies act against virions, vaccine
strategies targeted at conferring cellular immunity aim to
induce killing of infected cells upon recognition by CD8
cytotoxic T lymphocytes. This activity targets cells in
which viral protein synthesis is occurring and thus acting at
a later step in the infection cycle [25]. While the prevention
of infection achieved by neutralising antibodies may be
conceptually more desirable, the multitude of difficulties
experienced in eliciting sterilising immunity to HIV has
resulted in the consensus that an effective HIV vaccine will
need to induce both cellular and humoral immunity [25].
HIV vaccines – how can the hurdles
be overcome?
The hunt for an efficacious HIV vaccination regimen faces
several major obstacles, summarised in table 1. Firstly, im-
mune correlates of protection need to be defined. However,
as, once infected, humans do not naturally clear HIV, de-
termining which immune responses are capable of clearing
or even preventing infection, and thus which responses
vaccine design must elicit, is not simple.
During the natural course of infection individuals produce
HIV-specific antibodies and CD4 and CD8 T cell responses
in abundance [43]. Studies to determine which of these spe-
cific immune responses effectively limit viral replication in
vitro, and correlate with reduced viral load in vivo, have
been employed to predict potential correlates of protection
from HIV infection. While none of the immune responses
elicited in natural infection are capable of clearing HIV
infection, hope remains that blocking virus transmission
may be easier to achieve. HIV transmission is a stochast-
ic process, often involving only a single founder virus [44,
45]. In contrast, clearing an established retroviral infec-
tion, particularly once viral latency is established in long-
lived cells, is likely to involve a higher magnitude and dif-
ferent type of response. This may provide a window of
opportunity for HIV directed antibodies. Passive transfer
of broadly neutralising antibodies to HIV infected patients
can transiently suppress viral replication but does not lead
to viral clearance [46]. However, animal challenge studies
have demonstrated the ability of certain monoclonal anti-
bodies to prevent acquisition with neutralising antibodies
targeting specific epitopes [14, 16–18, 40, 47] or recruiting
specific immune effector functionality [42].
Another potential obstacle facing vaccine design is the di-
versity of circulating HIV strains [34]. Due to an error-
prone reverse transcriptase, and the capacity to recombine
genetic information from different strands of genomic viral
RNA during reverse transcription, HIV has the ability to
mutate rapidly to avoid antibody and T cell responses eli-
cited in natural infection [48]. As a result the virus exists
within the population as a diverse range of clades, strains
and quasispecies [34]. Historically efficacious vaccines for
genetically diverse viruses have been difficult to develop;
for example, the seasonal influenza vaccine, despite annual
adaptation to antigenic drift and shift of the circulating vir-
uses, achieves only moderate efficacy [49].
Yielding antibodies to specific epitopes through vaccin-
ation remains challenging [26]. In other viral infections
simply administering recombinant viral proteins can yield
protective antibody responses [28], but this has not been
the case for the poorly immunogenic and genetically di-
verse HIV envelope. No HIV proteins are entirely con-
served, and conserved epitopes that are accessible to neut-
ralising antibody attack are especially rare within the ex-
ternal envelope proteins of HIV. This is particularly re-
markable as the virus depends on several relatively con-
served domains within these envelope proteins to recognise
and enter its target cells [35]. As these domains, such as the
binding sites for CD4 and coreceptors, are the prime targets
for neutralising antibodies the virus has evolved to effect-
ively protect these sites. The HIV envelope is camouflaged
by dense, host-derived glycosylation which shields vulner-
able sites and hampers immune recognition [reviewed in
35]. Key domains in gp120 and gp41 are further hidden by
flexible and highly variable loops in gp120 and the qua-
ternary association into the trimetric viral spike, and only
exposed transiently on engagement with cellular receptors
[50]. Defining a single immunogen that will elicit a protect-
ive immune response against all genetic subtypes may not
be feasible. Consequently, vaccine immunogens may need
to be tailored to geographical variability in HIV diversity,
or present multiple antigens in order to elicit a broader
response, both strategies employed in the seasonal influ-
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enza vaccine (trivalent) or pneumococcal vaccines (up to
23-valent).
Administration of monomeric envelope immunogens has
yielded only limited success so far, as the monomeric pro-
teins expose epitopes hidden in the functional envelope tri-
mer and thus primarily elicit non-neutralising antibodies
[3, 4, 8]. Additionally, quaternary epitopes composed of
multiple protomers are not represented on the monomeric
proteins. Unfortunately, designing a stabilised immunogen
which resembles the native trimer has proven challenging
but becomes a more attainable goal as more is learnt about
the structural organization of the viral spike [37, 38].
Another potential impediment to HIV vaccine design has
been a narrow and perhaps naively optimistic vision of
what a vaccine should achieve. Although sterilising immu-
nity remains the ultimate goal, vaccine trial design must
broaden to recognize additional potential outcomes [51].
Based on the results of RV144, it has also become evident
that trial design needs to incorporate frequent measures
of immune activity and breakthrough viruses in order to
stratify analyses of protection, and characterise the type
of protection elicited. Vaccine regimen may induce im-
mune responses that do not protect against transmission,
yet succeed in clearing virus after few initial rounds of
replication. Hence, monitoring of vaccinees must include
measures capable of detecting and confirming transient in-
fections which may, for instance, be characterised by pos-
itive serology, but persistently undetectable viral load, an
outcome that may be achieved by a vaccine that educates
the immune system to recognize and eliminate HIV in-
fection. Alternatively, long-term follow-up of vaccinated
individuals who do become infected may detect vaccine-
induced control of viral load and delayed progression to
AIDS. These outcomes would also lead to reduced onward
transmission of HIV from infected vaccinees to their part-
ners, and thus could still have a dramatic impact on the epi-
demic [51].
HIV vaccines – where are we now?
Numerous preclinical studies and phase I and II clinical
trials have been conducted over recent decades in an at-
tempt to define immunogens capable of eliciting HIV-dir-
ected humoral and/or cellular immune responses [9, 52,
53]. In animal models, classical vaccine design strategies
that have succeeded rapidly for other viral infections have
failed to induce strong immune responses to HIV. Inactiv-
ated or killed virus, recombinant envelope proteins (gp120,
gp160, gp140, trimer), peptides (V3, MPER), or various
envelope scaffolds have been probed in various formula-
tions, including adjuvants and DNA prime boost regimen
[9]. DNA vaccine and various types of recombinant at-
tenuated vector regimen have elicited cellular responses
capable of controlling infection [25, 52, 53] or inducing
protection against transmission of homologous challenge
[54]. More recently, vaccine-induced antibodies have also
been implicated in protection against heterologous chal-
lenge [55]. In these models the potential for passive im-
munisation of neutralising antibodies to provide sterilising
immunity against viral challenge [14–17, 40], and for T
cell responses to control viral load [54] have also been af-
firmed.
Considering the logistical problems associated with testing
HIV vaccine efficacy in clinical trials (discussed in more
detail below), non-human primate (NHP) infection models
may need to be developed further to provide reliable indic-
ations that a regimen is immunogenic or efficacious before
initiation of human trials. Ideally the demonstration of ef-
ficacy in NHP challenge models combined with established
safety in human trials may qualify regimens for licensing.
However, thus far protection induced in NHP has not trans-
lated sufficiently into clinical trial success [56–58]. One
complication of current NHP studies is the need for hybrid
SIV/HIV virus strains which produce similar pathogenicity
to HIV and allow investigation of HIV-directed immune re-
sponses in NHPs. Few appropriate virus strains have been
identified so far [59], limiting the breadth of elicited immu-
nity that can be probed. While resembling HIV infection
and pathogenesis in many aspects, since these models can-
not recapitulate the human immune response or diversity
of HIV infection, they cannot replace large-scale phase IIb
proof-of-concept or phase III clinical efficacy trials.
Only a handful of immunisation regimens have been tested
in large-scale clinical efficacy trials. The first, a protein
immunogen composed of recombinant HIV envelope sub-
units, failed to demonstrate protection (in injection drug
users, AIDSVAX B/E [3], or high-risk MSM, AIDSVAX
B/B [4, 7]) despite eliciting antibodies capable of binding
and neutralising the immunisation strain in some patients
[4] and protecting chimpanzees from homologous chal-
lenge [57, 58].
Table 1: Remaining challenges in vaccine design.
General
• Correlates of protection remain undefined.
• Correlates of (mucosal) transmission remain undefined.
• Vaccines must elicit mucosal immune responses.
• Animal models capable of predicting efficacy of vaccines in human protection are required in order to reduce the need for human efficacy testing.
• Circulating strains of HIV demonstrate dramatic genetic diversity, rendering the development of a globally active vaccine difficult.
Antibody based vaccines
• The HIV envelope is poorly immunogenic.
• The HIV envelope shields conserved regions from antibody binding.
• An appropriate immunogen to elicit potent neutralising antibodies has not been identified.
• The in vivo mode of antibody activity (neutralisation and/or effector functions) remains to be ascertained.
T cell based vaccines
• Recombinant viral vector immunogens must be designed to induce protective cytotoxic and helper T cell responses in man.
• Safe immunogens which do not induce increased susceptibility to HIV infection must be defined.
• Pre-existing vector-directed immunity must be avoided.
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Following much evidence that CD8 induced cellular im-
munity controls viral load during natural infection [60, 61],
vaccine research shifted the focus towards recombinant vir-
al vector immunogens which generate viral proteins in host
cells and thus elicit T cell responses. Despite success in
preclinical assessments, the vaccine regimen designed to
elicit protective T cell responses has failed in human tri-
als [62]. These regimens had no impact on acquisition or
the viral load in those participants who became infected,
despite exhibiting this ability in NHP models [56], eliciting
HIV-specific T cell responses in most vaccinees [5] and ex-
hibiting immune pressure on breakthrough infections [63].
The two phase IIb trials designed to probe the efficacy of
a T cell based vaccine regimen using the replication-de-
fective adenovirus type 5 (Ad5) MRK gag/pol/nef vector
were stopped prematurely when the first interim analysis
showed that it had no impact on infection rate or early
plasma viral load. In fact, HIV infection rate was elevated
amongst a subgroup of vaccinated men who were pre-
viously Ad5-seropositive and uncircumcised [62], raising
safety concerns about this regimen. The mechanism caus-
ing this increase in susceptibility is not fully understood
but the transmission mode may have played a role as the
effect was observed in MSM but not in heterosexual par-
ticipants [62]. As increased infection appears to be asso-
ciated with pre-existing immunity to Ad5, the vector may
have stimulated Ad5 specific CD4 T cells and Ad5 anti-
body immune complex formation in Ad5-seropositive in-
dividuals. This immune activation could stimulate CD4 T
cells and dendritic cells, rendering cells more susceptible
to HIV [64]. While the mechanism responsible for higher
HIV acquisition during this trial has not been confirmed,
the impact of vector-directed immune activity must be con-
sidered in future trials [62].
The vaccine regimen employed in RV144 combined a ca-
narypox vector expressing LAI gag and protease, and
CRF01_AE gp120 with an LAI gp41 transmembrane
linker, followed by two protein boosters of AIDSVAX B/E,
the protein used in the earlier protein-only vaccine trial
study in Thailand [6]. Thus, in RV144 both B and T cell
directed strategies, neither of which had been successful in-
dividually, were combined in a prime-boost regimen. The
positive outcome of this trial, a 31% reduction in infection
risk in a primarily heterosexual population in Thailand,
thus surprised many and is still not fully understood since
the immune mechanisms responsible for this protection
have not yet been determined [8].
The quest for correlates of protection
The results of RV144 raised many questions. Although
moderate efficacy has been reported, the low level of HIV
acquisition occurring in the trial population of low-risk
volunteers equips statistical analysis with low power to
identify potential correlates of protection. Without further
verification in clinical trials any immune responses found
to correlate with reduced transmission may simply rep-
resent surrogate markers of immune activation. Extensive
work to define the window in which protection occurred
(persistence of protection), immune pressure exerted on
breakthrough viruses in vaccinees (sieve analysis) and im-
mune responses responsible for non-infection (immune
correlates of protection) has involved rapid widespread in-
ternational collaboration since the RV144 results were an-
nounced in 2009 [8]. Initial correlates analysis, thus far
unpublished but reported at the AIDS Vaccine Conference
2011 in Bangkok [65], revealed that the protection induced
by RV144 does not appear to be mediated by the usual sus-
pects. Neutralising antibody responses were rarely elicited
and did not correlate with reduced acquisition. Instead pro-
tection correlated with non-neutralising humoral responses
directed towards a particular epitope in the HIV envelope,
variable loop 2 (V2). Individuals with high V1V2 directed
IgG experienced a 43% reduction in HIV incidence, and
strains present in vaccinated but infected individuals pos-
sessed more highly mutated V2 loops, suggesting escape
mutation from the elicited antibody response. However, the
mechanism by which these antibodies elicit protection re-
mains to be determined [65]. One possibility is that these
V1/V2 binding antibodies mediated antibody-dependent
cellular cytotoxicity (ADCC), an immune response that al-
lows destruction of opsonised infected cells [66]. In NHP
challenge studies it has been demonstrated that the protec-
tion mediated by passive transfer of a broadly neutralising
antibody depends upon the ability of that antibody to medi-
ate Fc-receptor effector functions [42], of which ADCC is
one.
A feature of particular note is that the protective effect of
RV144 was only transient and the protective effect was
found to be statistically significant only during a relatively
narrow time window [8]. The latter aroused controversy on
the value of the observations, efficaciousness of the vac-
cine and the validity of the statistical methods employed
[67–69]. The period of peak immunogenicity, as determin-
ed by analysis of infection incidence, occurred two weeks
after the last boost vaccination and titres of V1/V2 binding
IgG declined in the following 6 months, suggesting that
any protection observed may have rapidly deteriorated.
This observation raises further questions. Was this protec-
tion mediated by humoral or CD8 T cell responses, and
did these responses act in concert with immunisation-in-
duced stimulation of the innate immune system? Most im-
portantly, could more frequent or further rounds of vaccin-
ation yield sustained protection?
The difficulty encountered in identifying correlates of pro-
tection in RV144 has highlighted the importance of design-
ing trials in a way which will provide both enough trans-
mission events to lend statistical power to sieve and correl-
ates analysis and sufficient biological material for immune
functionality to be thoroughly assessed. Simultaneously,
standardised in vitro assays must be defined to dissect and
assess the quantity and quality of specific humoral and cel-
lular immune responses directed towards the immunogen
administered.
Moving antibody based vaccines
ahead
Whilst protein immunogen regimens have elicited antibod-
ies capable of binding challenge strains, these immune re-
sponses appear to be limited by the same restricted breadth
apparent in natural infection [9]. Recently, however, isol-
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ated highly potent broadly neutralising antibodies have
confirmed that HIV infected individuals are able to pro-
duce precisely the kind of antibodies that are thought to
be ideal candidates to provide protective immunity [36].
Structural analysis of the epitopes targeted by broadly neut-
ralising antibodies has highlighted sites of vulnerability
in the HIV envelope that are conserved across multiple
strains, such as the gp120 CD4 binding site [12], gp120
V2V3 loops [10], gp120 glycans [10, 70] and gp41 MPER
region [71, 72]. However, such broadly neutralising anti-
bodies appear to be rarely elicited in vivo and some well
characterised broadly neutralising antibodies possess fairly
unusual characteristics (such as domain-swapped structure
[73] or self-reactivity [74]), long CDR3 regions [13, 75]
and many are highly affinity matured [10, 76]. Nonethe-
less, eliciting such antibodies by presentation of appropri-
ate protein immunogens remains one of the most prom-
ising yet challenging routes to vaccine design. The key lies
in defining an immunogen capable of overcoming the bar-
riers to the development of broad antibody responses en-
countered in natural infection and focusing the immune
response solely on the desired domain. Conformational
masking, glycan shields and a high degree of flexibility
combine to render the natural conformation of the viral en-
velope spike poorly immunogenic [37, 38]. Presenting the
required domains in an engineered immunogen capable of
maintaining and presenting this conformation without in-
terference from shielding factors is the ultimate goal [77].
This rapidly progressing field is termed reverse vaccino-
logy or rational design [77].
As discussed, all isolated HIV broadly neutralising anti-
bodies have undergone a high level of affinity maturation.
Therefore, despite construction of antigens expressing the
epitopes of these antibodies, vaccinees may not be able to
elicit similar antibodies immediately. Instead, identifying
the germline precursor and partially matured ancestor an-
tibodies that lead to development of the broadly neutral-
ising paratope may inform design of a series of immuno-
gens capable of guiding antibody maturation in vivo.
How much antibody must a vaccine elicit to be protective?
Maintaining high antibody levels for prolonged periods
may be difficult if vaccination is not boosted at regular in-
tervals. NHP passive transfer studies have determined that
the protection conferred by neutralising antibodies typic-
ally requires sera antibody concentrations that exceed the
in vitro inhibitory dose 100 fold [14, 16, 17, 40, 78]. The
same range of activity was found in human passive immun-
isation [46, 79]. Thus, if a vaccine is capable of eliciting
approx. 10 µg/ml of an antibody [80], then the potency of
that Ab must provide broad neutralisation with an inhibit-
ory dose of less than 0.1 µg/ml. If elicited individually or in
combination, the new highly-potent highly-broad antibod-
ies may achieve this with increased breadth [13].
Will anti-retroviral treatment thrive
where HIV vaccines have failed so
far?
While prophylactic measures such as condom use [81] and
male circumcision [82] dramatically reduce HIV transmis-
sion, they have not been practised sufficiently to halt the
epidemic. Although no pharmaceutical regimen has yet
provided a cure, patients with undetectable viral load are
certainly less infectious, emphasising that appropriate pre-
scription of anti-retroviral therapy (ART) can have a sig-
nificant impact on the epidemic [83]. Recent publications
have highlighted the potential of “treatment as prevention”
[84, 85], and evidence that the prescription of certain small
molecule anti-retrovirals to uninfected individuals serves
as a prophylactic prevention strategy (preexposure prophy-
laxis, PrEP) is accruing [86, 87]. Both of these strategies
are more efficacious in preventing transmission than the
only effective vaccine tested to date [8]. However, while
compelling in terms of efficacy widespread implementa-
tion of PrEP faces enormous difficulties. The fact remains
that the majority of those infected with HIV worldwide do
not have access to expensive anti-retroviral drugs even to
treat infection [2]. Extending provision of lifelong ART not
only to all infected individuals but potentially all at-risk in-
dividuals also, faces significant operational and financial
hurdles and is unlikely to be the most cost-effective route
to HIV elimination. In contrast, even a moderately effective
vaccine could rapidly have tremendous impact [33]. Em-
ploying PrEP as an eradication strategy would depend upon
a high degree of compliance by a large proportion of the
population for many years. Sustained systemic treatment
of healthy individuals with the currently approved anti-ret-
rovirals is likely to do more harm than good, in view of
the adverse effects associated with these medications [88].
Therefore, it is likely that PrEP will be restricted to certain
high-risk settings and administered as required.
Many of these concerns also apply to microbicides, topic-
ally applied anti-retrovirals [87], although topical applica-
tion may circumvent adverse effects and allow more wide-
spread administration. In contrast, an effective vaccine may
provide sustained protection following only a few immun-
isations.
Combining PrEP and vaccination
Inclusion of efficacious PrEP provision in HIV vaccine tri-
als would certainly change the landscape of vaccine trial
design. Efficacy trials in high-risk populations (AIDSVAX
[3, 4] and STEP [5]) have found an incidence rate of 3–6%
per annum, and in RV144 the incidence was well below
1%. These relatively low incidences render efficacy, sieve
and correlate of protection analysis low-powered, and thus
limit capability of detecting moderate efficacy or determin-
ing the mechanism of protection. In comparison, a vaginal
microbicide containing tenofovir studied in the CAPRISA
trial reduced HIV transmission to women during hetero-
sexual intercourse by 39% [87]. Once microbicide efficacy
is confirmed, this intervention may need to be recognised
as a new standard of care, and thus will need to be provided
during vaccine trials to both vaccine and placebo arms
[89, 90]. In these circumstances the incidence of infection
would decrease by at least 30–50%; a trial such as RV144,
which followed 16,402 participants for 3.5 years and de-
tected only 125 infections, would be under-powered to re-
trieve data for outcome analysis.
Ignoring difficulties in distribution, PrEP and microbicides
are currently the most effective pharmaceutical measures
Current opinion Swiss Med Wkly. 2012;142:w13535
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 8
we have to protect in high risk settings. It is clear that vac-
cine development will require many more years to yield po-
tent protection. In the meantime, targeting a lower-efficacy
vaccine to a high proportion of the population, with simul-
taneous implementation PrEP for those at high risk, may be
the most efficient route to eradication.
Both antibody and T cell based vaccines depend on elicit-
ing potent CD4 T cell responses. Inducing activated CD4 T
cells, which are highly susceptible to HIV acquisition [91],
maybe a risky undertaking if no countermeasures are em-
ployed, as the outcome of the STEP trial suggested [62]. A
combination of vaccination with PrEP may, in fact, over-
come this potential adverse effect and provide added pro-
tection during the time vaccination stimulates and builds up
immunity to HIV.
The quest continues
Despite the many remaining challenges, the goal of an ef-
ficacious HIV vaccine is more attainable now than ever.
The immunogens currently undergoing clinical investig-
ation [53, 88] have benefitted from the development of
strong animal challenge models, and standardised in vitro
assays for detection of elicited humoral and cellular immu-
nity. Correlates of protection may yet be forthcoming from
the RV144 trial analysis and further ongoing trials.
If the window of opportunity for conventional vaccine tri-
als is being closed by efficacious PrEP, alternatives to
large-scale efficacy testing must be found before the po-
tential for eradication of HIV through vaccination is lost.
In our opinion precise definition of the correlates of pro-
tection, together with efficacy testing in improved animal
models, appears to be the only solution. Once efficacy of
a given vaccine regimen has been defined in animal mod-
els and correlates of protection for this regimen have been
defined in both animal models and medium sized human
trials, vaccine licensing requirements could be relaxed to
allow specific measures of immunogenicity to stand in as a
surrogate for efficacy.
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